Metastatic Pancreatic Cancer: Deployed as a first-line maintenance therapy for gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on a platinum-based chemotherapy regimen.

HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC): Prescribed for patients with homologous recombination repair (HRR) gene-mutated mCRPC who have progressed following prior treatment with enzalutamide or abiraterone.

2. Mechanism of Action: How Brcaone Works

3. Administration and Dosing Guide

• Administration Route: Brcaone 150 mg is an oral tablet formulation. It must be swallowed whole with water and should never be chewed, crushed, dissolved, or split.

• Food Interactions: Tablets can be taken consistently either with or without food.

• Standard Schedule: The typical recommended adult dosage is 300 mg (two 150 mg tablets) taken orally twice daily, roughly 12 hours apart, making a total daily dose of 600 mg. Dose titrations or temporary interruptions may be managed by the treating oncologist based on individual hematological tolerance.

⚠️ Safety, Side Effects, and Monitoring

MDS/AML Risks: Rare but serious instances of Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) have been reported in patients receiving PARP inhibitors.

Pneumonitis: Rare cases of severe respiratory inflammation can occur. Patients presenting with new or worsening respiratory symptoms (dyspnea, cough, fever) must be evaluated immediately.